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This review describes the current evidence and controversies for
viability imaging to direct revascularization decisions and the impact
on patient outcomes. Balancing procedural risks and possible benefit
from revascularization is a key question in patients with heart failure of
ischemic origin (IHF). Different stages of ischemia induce adaptive
changes in myocardial metabolism and function. Viable but dysfunc-
tional myocardium has the potential to recover after restoring blood
flow. Modern imaging techniques demonstrate different aspects of
viable myocardium; perfusion (single-photon emission computed to-
mography [SPECT], positron emission tomography [PET], cardiovas-
cular magnetic resonance [CMR]), cell metabolism (PET), cell
membrane integrity and mitochondrial function (201Tl andReceived for publication November 5, 2018. Accepted April 28, 2019.
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Cet article decrit les donnees à l’appui de l’imagerie de viabilite en tant
qu’outil pour orienter les decisions en matière de revascularisation, les
controverses qu’elle suscite et ses repercussions sur les resultats pour
les patients. Trouver l’equilibre entre les risques lies à l’intervention et
le bienfait possible de la revascularisation est un enjeu fondamental
chez les patients presentant une insuffisance cardiaque d’origine
ischemique. Les differents stades de l’ischemie entraînent des
changements adaptatifs dans le metabolisme et le fonctionnement du
myocarde. Un myocarde dysfonctionnel mais viable est capable de se
retablir dès lors que le debit sanguin est retabli. Les techniques
d’imagerie moderne permettent d’observer les differents elements
d’un myocarde viable : perfusion (tomographie d’emissionDespite recent advances in the treatment of cardiovascular Fundamental Concepts Regarding Viability
(CV) disease, heart failure (HF) continues to cause significant
morbidity and mortality, driven by coronary artery disease
(CAD) in two thirds of patients with HF.1 The challenge is to
define which patients with HF of ischemic origin (IHF) will
benefit from a strategy of revascularization in addition to
guideline directed medical therapy (GDMT), which is the
mainstay of treatment in these patients.Imaging
In patients with IHF, left ventricle (LV) dysfunction can
result from scar, stress-induced ischemia, resting ischemia,
remodelling, stunning, hibernation, or a combination of these
processes. To understand the potential benefits of revascu-
larization, knowledge of the different myocardial states in IHF
is essential.2-7
Myocardial ischemia refers to a state of inadequate oxygen
delivery that cannot meet the myocardium’s metabolic
demand.8 The severity of inadequate flow will determine the
intrinsic molecular adaptations of the myocardium and
accounts for both the time course and the extent of revers-
ibility after a successful revascularization.8
Dysfunctional but viable myocardium develops as an adap-
tation to ischemia of varying degrees of severity and duration
(after acute, subacute, or persistent perfusion deficits) notll rights reserved.
99mTc-based SPECT), contractile reserve (stress echocardiography,
CMR) and scar (CMR). Observational studies suggest that patients with
IHF and significant viable myocardium may benefit from revasculari-
zation compared with medical treatment alone but that in patients
without significant viability, revascularization appears to offer no sur-
vival benefit or could even worsen the outcome. This was not sup-
ported by 2 randomized trials (Surgical Treatment for Ischemic Heart
Failure [STICH] and PET and Recovery Following Revascularization
[PARR] -2) although post-hoc analyses suggest that benefit can be
achieved if decisions had been strictly based on viability imaging
recommendations. Based on current evidence, viability testing should
not be the routine for all patients with IHF considered for revasculari-
zation but rather integrated with clinical data to guide decisions on
revascularization of high-risk patients with comorbidities.
monophotonique [TEM], tomographie par emission de positons [TEP],
resonance magnetique cardiovasculaire [RMC]), metabolisme cellu-
laire (TEP), integrite des membranes cellulaires et fonction mito-
chondriale (TEM après injection de 201Tl et de 99mTc), reserve
contractile (echocardiographie à l’effort, RMC) et tissu cicatriciel
(RMC). Les etudes observationnelles indiquent que les patients
atteints d’une insuffisance cardiaque d’origine ischemique dont la
viabilite myocardique est importante pourraient tirer des bienfaits de
la revascularisation, au lieu de recevoir seulement un traitement
pharmacologique, mais que chez les patients dont la viabilite myo-
cardique est moindre, la revascularisation ne semble offrir aucun
bienfait sur le plan de la survie et pourrait même aggraver le pronostic.
Ce constat n’a pas ete confirme dans deux etudes à repartition
aleatoire (etudes STICH [Surgical Treatment for Ischemic Heart Failure]
et PARR [PET and Recovery Following Revascularization] -2), bien que
les analyses post-hoc indiquent qu’un bienfait peut être obtenu si les
decisions reposent uniquement sur les recommandations relatives à
l’imagerie de viabilite. D’après les donnees probantes actuelles, les
epreuves de viabilite ne doivent pas être systematiques chez tous les
patients atteints d’une insuffisance cardiaque d’origine ischemique
chez qui la revascularisation est envisagee. Leurs resultats doivent
plutôt être integres aux donnees cliniques pour orienter les decisions
concernant la revascularisation chez les patients à risque eleve
presentant des comorbidites.
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Volume 35 2019severe enough to cause cell death.3 The resting contractile
function is altered, but the myocytes are still alive, and cell
dysfunction can be reversed after coronary flow is restored.
Three types of response can occur and present a partially
overlapping continuum: remodelling, stunning, and hiberna-
tion (Fig. 19-15).
Myocardium in jeopardy refers to ischemic and/or viable
tissue.
In nonviable myocardium, scar occurs when cell death is
irreversible and noncontracting (fibrotic) tissue replaces the
normal myocardium. Scar can be transmural or involve only
part of the wall thickness. Viability testing aims to prospec-
tively differentiate scar from jeopardized myocardium that has
the potential to recover after revascularization.Clinical Evidence for Viability Testing
Although there exists an abundance of nonrandomized
data that suggest the presence of viability can define patients
likely to benefit from revascularization,3,16-20 randomized
studies to date have not demonstrated statistically significant
differences.4,16,21-23 There are some observational data to
suggest that the extent of hibernating myocardium can predict
the likelihood of outcome benefit or recovery 5,24-27 and post-
hoc randomized controlled trial (RCT) data observed that if
there is adherence to imaging-based recommendations, there
may be outcome benefit.4,16,28
Revascularization carries inherent upfront risks of mortality
and morbidity, which are more pronounced in patients with
HF. When revascularization is considered in patients with
IHF, 2 important questions arise: first, does revascularization
benefit patients with severe HF and, second, is viability testing
of additional value in decision making?
The Surgical Treatment for Ischemic Heart Failure
(STICH) extension study showed a long-term (10-year)survival benefit from coronary artery bypass grafting (CABG)
compared with optimal medical therapy (OMT) in patients
with LV dysfunction and target vessels suitable for revascu-
larization.29 However, given the conflicting and scarce evi-
dence,21,30 revascularization is not necessarily the treatment of
choice for all. Viability testing might be beneficial in these
cases. A multitude of observational studies suggest the pres-
ence of viable myocardium results in better recovery in LV
function3,17,25,31 and survival after revasculariza-
tion.3,16,17,24,26 Further, studies have shown that the extent of
viability correlates with the magnitude of improvement in HF
symptoms post-surgery25,27 and that positron emission to-
mography (PET)-guided management results in improved
quality of life.32 However, these results are not consistent
across studies.22,33,34
Many previous studies are limited by retrospective design
with possible selection bias, and many predate the use of
current evidence-based medications. Six meta-analyses of this
topic have been published since 2002.3,18,19 Their findings
were that the beneficial effect of revascularization is largely
dependent on the presence of myocardial viability. From
Orlandini et al., 32 nonrandomized studies with 4328 pa-
tients and 4 randomized studies with 1079 patients were
combined.19 The results from nonrandomized studies sug-
gested significant mortality benefit from revascularization only
in patients with viability. However, no mortality benefit from
revascularization was evident in the 4 randomized studies,
leaving the overall interpretation of these results inconclusive.
There are 2 large randomized studies to address the
question of viability testing in revascularization. The PET and
Recovery Following Revascularization (PARR)-2 was the first
study designed to answer to this question;4 430 patients with
left-ventricular ejection fraction (LVEF)  35% from 9 cen-
tres were randomized to either viability assessment with
18fluordeoxyglucose (FDG)-PET or standard care without
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Viability Testing in Heart Failure PatientsPET. There was a trend toward benefit for the primary
outcome (cardiac death, myocardial infarction, and cardiac
hospitalization) at 1 year in the PET arm. However, not all
the patients were treated according to what the imaging
findings recommended. In a post-hoc analysis, a significant
reduction in outcomes was observed in the PET arm (hazard
ratio [HR] 0.62; P ¼ 0.019) in the cohort in whom man-
agement decisions adhered to the imaging recommendations
(75% of cases). Long-term (5-year) follow-up showed similar
findings (HR 0.73; P ¼ 0.042).16
The importance of expert image interpretation and subse-
quent clinical decision making was highlighted in the Ottawa-5
substudy that had 111 patients from an experienced centre with
interpretation expertise and easy access to FDG-PET.28 In this
scenario, patients in the PET arm had a clear benefit when
compared with standard care (19% vs 41%) at 1 year (HR 0.34;
P ¼ 0.005). In addition, the amount of hibernating myocar-
dium plays an important role in patient outcome (Supplemental
Fig. S1). Ling et al. showed that with increased extent of
mismatch (hibernating myocardium), the likelihood of benefit
with revascularization also increased.24 In a PARR-2 substudy, a
cutoff of 7% distinguished patients who would or would not
benefit from revascularization.5 Similar cutoffs of 5% to 10%
have been found in other studies.24,25
In the STICH trial,22 1212 patients with ischemic LV
dysfunction (EF 35%) and severeCADeligible forCABGwere
randomized to CABGþOMT or OMT alone. Patients with
50% left main disease or class III to IV angina were excluded.
There was no significant reduction in mortality at 5 years but a
significant reduction in mortality in the extension study after 10
years (all-cause mortality 58.9% vs 66.1%, P ¼ 0.02, CV mor-
tality 40.5% vs 49.3%, P¼ 0.006).29 There are some important
limitations to this trial: namely, the crossover among groups and
enrollment of patients without significant clinical HF (39%New
York Heart Association [NYHA] class I-II).
The viability substudy of STICH looked at the outcome of
601 patients who, in a nonrandomized fashion, underwent
viability testing with single-photon emission computed to-
mography (SPECT), dobutamine stress echo, or both.34
Viability was defined in a binary manner; 487 (81%) had
viable myocardium. At a median follow-up of 5.1 years, there
was no outcome difference in patients with viability according
to the randomized treatment strategy (CABG þ OMT vs
OMT alone). The STICH viability study was limited by the
nonrandomized selection for viability testing, not using more
advanced methods (cardiovascular magnetic resonance [CMR]
or PET), LV remodelling (mean LV end-diastolic volume
index was severely dilated 123 mL/m2), and the observation
that very few patients (19%) did not have viable myocardium.
The distinctions from PARR-2 and the STICH viability
substudy may be explained by differences in patient selection,
imaging modalities, and study methodology (Supplemental
Table S1).
There are 2 other small RCTs. The Healing and Early
Afterload Reducing Therapy (HEART) trial used stress echo-
cardiography and randomized 138 patients with CAD and
LVEF  35% to conservative therapy or angiography with the
intention to revascularization and showed no outcome differ-
ence but was acknowledged to be underpowered.21 Siebelink
randomized 103 patients to FDG PET vs 99mTc-MIBI
SPECT and showed no outcome difference.23 Only 36 (35%)of the 103 patients had reduced EF 30%.23 The small sample
sizes of these studies precluded any definitive conclusions.Imaging Modalities to Assess Myocardial
Viability
The techniques for assessing myocardial viability are based
on detecting one or more of the markers of dysfunctional
myocardium: perfusion, cell metabolism, mitochondrial
function, cell membrane integrity, contractile reserve, and scar
(Table 1). All these modalities have advantages and disad-
vantages (Table 1). Respectively, all these methods can be
used with good accuracy (Supplemental Fig. S2) when inter-
preted by acknowledged experts.
Dobutamine stress echocardiography
Dobutamine stress echocardiography (DSE) is used to assess
regional myocardial contractile reserve.35 Low-dose dobutamine
can lead to increased contractility in dysfunctional segments
that are viable. At higher doses, viable segments may further
improve or show reductions in contraction, reflecting inducible
ischemia, but will not show incremental contractility if they are
scarred.26,36,37 The reported sensitivity and specificity of DSE
are 80% and 78%, respectively, in predicting regional LV
function improvement following revascularization, considered
the most specific of the methods in experienced hands3
(Supplemental Fig. S2). Intravenous contrast agents can be
used to improve the accuracy of DSE. Further, speckle tracking
imaging represents a novel additional echo method to assess
viability that can be used both at rest or with stress.38,39
SPECT
SPECT is a widely available modality with well-established
clinical and prognostic validation.40 Radionuclide-labelled
tracers sequester within myocytes with intact cell mem-
branes and the regional concentration is compared with the
peak uptake to assess viability. The most widely used tracers
for viability imaging are the potassium analog thallium-201
(201Tl) and lipophilic intramitochondrial molecule
technetium-99m (99mTc)-labelled compounds, whereby
their cardiac uptake reflects sarcolemma membrane integrity
and mitochondrial function, respectively.3,41 Compared with
techniques based on the assessment of residual contractile
recovery, SPECT has higher sensitivity and lower specificity.3
PET
PET imaging using perfusion tracers such as 13N-labelled
ammonia (13NH3) or Rubidium-82 (82Rb) combined with
images using the glucose analog 18F-FDG is an effective
technique to provide information on both myocardial perfusion
and metabolism.42-44 Concordant reduction in both perfusion
and FDG uptake (“flow-metabolism match”) indicates irre-
versibly injured scarred myocardium, whereas regions in which
FDG uptake is increased relative to a perfusion defect (“flow-
metabolism mismatch”) represent myocardial hibernation
(Table 2). Healthy myocardium also uses glucose in the non-
fasting state. The preparation for FDG PET viability imaging is
straightforward and involves a 12-hour fast, then an oral glucose
load, and then monitoring of glucose levels. Patients with
abnormal glucose response will receive insulin. In patients with
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     Remodelling 
Compensatory myocyte changes taking place in viable dysfunctional myocardium but also in remote normally perfused regions 
to maintain cardiac output. The changes in ventricular geometry, local wall strain, filling pressures, and neurohormonal factors 
initially induce compensatory hypertrophy, but, in the long term, deleterious adverse remodelling and ventricular dilatation 
occurs.10,11
     Stunning
Reversible contractile dysfunction after abrupt, transient ischemia.6 This situation normally occurs after a single brief episode of 
ischemia in which, after prompt restoration of blood flow, the contractile dysfunction persists temporarily followed by recovery 
(which may be minutes, hours, days, or weeks). 
     Hibernation  
Result from repetitive stunning, repeated episodes of ischemia, persistent perfusion defects at rest, or reductions in the 
coronary flow reserve. 8,12,13 The contractile function at rest is reduced, what is thought to be a protective mechanism to 
downregulate oxygen consumption (and downregulation of perfusion) to ensure myocyte survival.6,8,12 By definition, hibernating 
myocardium has the potential to recover with restoration of normal blood flow, and therefore it can only be defined with 
certainty after revascularization.  Serial histologic and proteomic studies post-revascularization have shown that, for the most 
part, the cellular changes are recoverable.7
Figure 1. Definitions and cellular differences between normal and different types of viable dysfunctional myocardium. Adapted from Bayeva et al.8
and Frangogiannis et al.14 Pictures from Vanoverschelde et al.:15 light microscopy pictures (on the left) and electron microscopy pictures (on the
right); with permission from Wolters Kluwer Health.
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Volume 35 2019known diabetes, the insulin clamp is the preferred approach, as
it yields the best quality images.45 An example of a PET
viability study is shown in Figure 2.46
CMR
CMR, combined with the use of gadolinium-chelated
contrast agents, can provide information on perfusion andviability concomitantly. Gadolinium does not penetrate myo-
cytes with intact membranes. The contrast agent has a greater
volume of distribution into regions of altered cell permeability,
as occurs in scarred or acutely infarcted tissue, enabling the
assessment of the transmurality of necrosis and the presence of
viable tissue. In conjunction with dobutamine stress, CMR can
also provide information on global LV function, regional wall
motion, and thickening.47 Romero et al. pooled 24 CMR
Table 1. Imaging modalities to assess myocardial viability
Modality Mechanism Findings indicative of viability Advantages/disadvantages
Dobutamine echocardiography/
CMR
Contractile reserve* Improvement by visual or strain rate
imaging (echo)
A: Specific, widely available, without
radiation, can detect ischemia, assesses
valvular disease








> 50% of maximum
A: Widely available, moderate cost















D: Limited availability, high cost, need




Scarring (LGE) < 50% wall thickness
Systolic thickening of a dyskinetic
segment
A: Highly sensitive, without radiation,
assesses valvular disease
D: Limited availability, high cost, risks in
renal failure, cannot use with certain
devices
CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; PET, positron emission tomography SPECT, single-photon emission computed
tomography.
* Biphasic response. Dobutamine low dose 5 to 10 mg/kg/min leads to improved contractility in hibernating myocardium. Dobutamine high dose up to 40 mg/
kg/min (þatropine) leads to increased oxygen consumption, induced ischemia, and decreased contractility.
yRisk of potentially life-threatening complications 0.2%.37
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improvement after revascularization. They found that delayed
gadolinium enhancement < 50% of wall thickness, > 2 mm
wall motion change in low-dose dobutamine infusion, and
> 5.5-mm to 6-mm end-diastolic wall thickness predicted
functionmyocardial recoverymeasured by serial CMR.20 There
are data supporting that even when the end-diastolic wall
thickness is 5.5 mm, there is potential for recovery as long as
the scar is not transmural.48 Dobutamine CMR can detect
ischemia and viabity by contractive reserve. Adenosine CMR
can detect perfusion and define regions at risk of ischemia.
Native T1 tissue mapping is an emerging method to assess
transmurality of infarctionwithout contrastmaterial.49 Figure 3
illustrates an example of a CMR study.
Data regarding cost effectiveness of viability testing and the
different modalities are limited. One study applied a “decision
analysis model” that evaluated patients undergoing revacula-
rization or not and PET imaging or not; an algorithm was
developed. They demonstrated that viability PET imaging
“may be cost effective in the selection of patients with poor
LV function referred for CABG.”50
The optimal choice of which modality to use is deter-
mined, in part, by patient characteristics and local factors
(expertise, availability, and practice patterns). In the absence
of direct comparative outcome evidence, the authors suggest
the following approach:51,52
1. Moderate LV dysfunction: any modality with local
expertise.
2. Severe LV dysfunction: nuclear methods (SPECT, PET) or
CMR late gadolinium enhancement (LGE), which are
more sensitive than contractile reserve.3,203. Renal failure (GFR < 30) or CMR incompatible devices;
avoid CMR.
4. Critical left main or proximal 3-vessel disease; avoid
dobutamine.
5. Equivocal or negative results on another viability test, in
which certainty is needed to completely rule (in or) out
viability; consider PET or CMR as highly sensitive
methods.3,20
Clinical Perspective
The decision whether to revascularize a patient with signifi-
cant LV dysfunction can be one of the most difficult decisions in
medical practice, notably in patients without significant ischemia
or angina. As RCT data have not supported routine use of
viability imaging in IHF, its use should be limited to situations in
which decisions are most difficult. Based on post-hoc analyses and
observational data, viability imaging may contribute to risk
stratification and selection of patients considered eligible for
myocardial revascularization.3,4,16,18-20,28,53
GDMT includes optimal pharmacological and non-
pharmacological therapy for all patients and implantable-device
therapy for appropriately selected patients as key therapies for
patients with IHF. The selection for percutaneous mitral valve
procedures is still in evolution.54,55 In addition, LV-assist de-
vices and cardiac transplantation are advanced treatment op-
tions for a minority of patients. Revascularization offers the
potential for improved survival and quality of life for certain
patients with IHF.25,27,29,32,56 Post-hoc RCT and observational
data suggest that this may be particularly true for patients with
high ischemic burden and viable myocardium and/or low scar
burden.3,4,16,18-20,28,53,56 Other potentially useful parameters
to guide therapeutic strategies include remodelling, LVEF, right
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Hibernation Reduced Preserved or increased
(¼ perfusion-
metabolism mismatch)
Reduced Yes some* May have partial /delayed




Ischemia Preserved at rest, impaired
at stress
Normal at rest, increased at
stress
Preserved at rest, impaired
at stress





Scar Reduced Reduced Absent Fibrosis Unlikely to recover with or
without
revascularization
Data from multiple sources.3-6,10,16,24,28,46,51,52,69
FDG, 18F-fluorodeoxyglucose.
* See Figure 1.
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Volume 35 2019ventricular failure, pulmonary hypertension, mitral or tricuspid
regurgitation, as well as duration of cardiac dysfunction as
suggested by Bax et al. and others.53,57 However, the intersec-
tion and application of these complex parameters into a clinical
decision remains a challenge.
Guideline-driven management supports revascularization
for patients with IHF if they have reversible ischemia or a
significant amount of viable myocardium above the method-
specific cutoffs (Table 3).58 Assessment should include scar
burden (defined as the total amount of scar in the LV
expressed as a percentage of the total LV), as it is an inde-
pendent prognostic factor as well as an important variable for
treatment choice.20,31 The degree of LV remodelling also
plays an important role. It is known that advanced remodel-
ling in IHF is associated with poor outcomes, regardless of
presence of viability/ischemia.59-61 In at least 1 study, even
viable myocardium did not improve with revascularization in
the context of extensive remodelling.62 On the other hand,
others suggest that a larger LV end-systolic volume index
(LVESVI) > 79 mL/m2) actually favours revascularization.63
Therefore, the data on the interaction of remodelling and
viability extent are contradictory and, at present, there are no
validated remodelling cutoffs for revascularization benefit.61-63
Viability testing should be limited to patients with IHF for
whom revascularization decisions are ambiguous and most
difficult, such as patients without angina or demonstrated
reversible ischemia with moderate-to-large regions of fixed
perfusion defects and/or with multiple comorbidities
(Table 4). In some patients, the decision to revascularize is less
controversial, and, in this cohort, viability testing is unlikely to
be of benefit.51,63 These characteristics are angina Canadian
Cardiovascular Society (CCS) > II, patients with normal or
mild LV dysfunction, critical left main CAD, patients with
good revascularization targets, those with already demon-
strated moderate-to-severe ischemia, and those with minimal
or no comorbidities.52,63The assessment of myocardial viability with noninvasive
imaging modalities may be of importance in certain cohorts,
such as patients with chronic total occlusions (CTOs) before
the decision for revascularization is made.64,65 Table 4 lists
important clinical and imaging variables that can aid in the
decision for requesting viability testing for patients with HF
with reduced EF (HFrEF). This is based on the best current
knowledge and evidence that, unfortunately, does not include
high-quality data achieved through very large well-powered
randomized controlled outcome trials.51,63-65
Several recently proposed algorithms could be adopted for
viability testing in clinical practice.52,66,67 The presence of
ischemic symptoms may define patients who will derive
symptomatic benefit from revascularization.68,69
Patients who have predominantly HF symptomsmay beneft
from viability testing if they have low-to-intermediate proce-
dural risks without high-risk coronary anatomy features (Fig. 4).Contributing Factors to Clinical Decision Making
The total amount of myocardium in jeopardy (viable and/
or ischemic myocardium) is intuitively pivotal regarding the
benefit from revascularization, although most studies have
addressed them separately, and some have shown contradic-
tory results. In the analysis of Ling et al., for 648 patients with
mean LVEF of 31% undergoing PET, the percentage of
viability was prognostic for benefit from revascularization, but
ischemia and scar were not.24 Further, in STICH, inducible
ischemia with stress SPECT or dobutamine echocardiography
did not correlate with survival prognosis, which was similar to
the findings from STICH viability assessment discussed pre-
viously.70 In a trial of 719 patients mostly without HF (only
15% with HFrEF), the patients with moderate-to-high
ischemia burden on stress SPECT had better long-term out-
comes after undergoing timely revascularization compared
with pharmacological therapy only.71 Complementary
Figure 2. (A) Rest N-13-ammonia perfusion (Rst, top row) and 18FDG metabolism (FDG, bottom row) PET viability study in a patient with docu-
mented multivessel disease to aid in revascularization decision making. Perfusion images demonstrate moderate to severe reduction in tracer
uptake in the left anterior descending (LAD) territory and moderate reduction in uptake in the basal to mid inferolateral wall (RCA/LCX territory). The
FDG images demonstrate an extensive area of mismatch in the mid to distal anterior wall and apex (white arrows). (B) Polar map with quantitative
analysis of the scar amount (7%, match defect) on the bottom left and hibernating myocardium (22%, mismatch defect) on the bottom right. Given
the significant amount of hibernating myocardium, coronary artery bypass grafting was recommended. Reproduced from Wiefels et al.46 with
permission form Springer Nature.
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mainly patients who did not have HF, optimal medical
therapy was superior to revascularization in patients with
minimal ischemia.72 The International Study of Comparative
Health Effectiveness With Medical and Invasive Approaches
(ISCHEMIA) trial, which recently completed enrollment, will
shed further light on this concept, although not in patients
with more severe LV dysfunction (https://clinicaltrials.gov,
NCT01471522).
The upfront risk of operative mortality is greater in pa-
tients with severe LV dysfunction and needs to be balanced
with the possible long-term benefit. The utility of viability
testing seems to be greatest in patients for whom both the
risks and benefits of revascularization are the highest. A meta-
analysis of 26 observational studies with 4119 patients (mean
age 64 years, LVEF  35%) undergoing CABG showed an
operative mortality of 5.4%.73 Surgical mortality risk calcu-
lators, such as European System for Cardiac Operative Risk
Evaluation (EuroSCORE II), (http://www.euroscore.org/calc.
html) and the Society of Thoracic Surgeons (STS) score
(http://riskcalc.sts.org/STSWebRiskCalc273/de.aspx) should
be used for guidance. In the STICH trial, the early increasedrisk with CABG and long-term benefit curves crossed at 2
years, and thereafter mortality was lower in the CABG
subgroup.22
The arrhythmogenic potential of viable myocardium might
play an important role. Studies have shown that the prognostic
benefit of revascularization in patients with viability is not tied
to improved LV function alone.74,75 One mechanism for the
mortality reduction is related to revascularization of myocardial
regions with potential to cause lethal arrhythmias.76,77 Sym-
pathetic nerves are more sensitive to ischemia compared with
the myocytes. The Prediction of Arrhythmic EventsWith PET
(PAREPET) study demonstrated that a greater amount of
sympathetic denervation measured by 11C-HED-PET corre-
lated with greater risk of sudden cardiac arrest.78 In another
study using voltage mapping, it was demonstrated that hiber-
nating myocardium displays abnormal and heterogeneous
properties, creating arrhythmogenic potential.79Guidelines for Viability Imaging in Heart Failure
The current task force guidelines from CCS, American
College of Cardiology Foundation/American Heart
Figure 2. Continued.
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Volume 35 2019Association (ACCF/AHA) and European Society of Cardiol-
ogy (ESC) offer only general recommendations regarding
viability imaging. They state that imaging for myocardial
viability (and ischemia) is reasonable in select situations in
patients with HF who are considered suitable for revascular-
ization80 and that noninvasive imaging modalities might
provide critical information needed,81 although the limited
experience from RCTs has not been able to demonstrate the
routine benefit from viability testing.58,68,80,81 For recent
heart failure guidelines, the class of recommendations for
viability imaging is graded IIA (should be considered, level of
evidence B-C)80 or IIB (may be considered, level of evidence
B),68,81 largely because of the lack of support from large
RCTs.Ongoing Trials and Future Directions
The results of the STICH viability study questioned the
value of viability testing and likely led to decreased use of
viability imaging (or perhaps less inappropriate testing). The
journey of viability testing is a fine example of constantly
evolving knowledge translation and best practices of seemingly
well-established concepts. It has become apparent that con-
ducting a randomized study on the benefit of viability testing
in guiding revascularization is challenging, as therapeutic de-
cision making is difficult to control. Without supporting data
from the existing RCTs, it is clear that not all patients with
HF and CAD require viability testing before revascularization
decisions.4,16,21-23,34 Specifically, viability imaging is not
likely to add value in patients with already documented
Figure 3. (A) Cardiac magnetic resonance (CMR) images of a patient with a history of previous anterior myocardial infarction and occluded mid-left
anterior descending (LAD) artery on coronary angiogram showing subendocardial scar involving > 75% of the myocardium from the basal to apical
anteroseptal wall, mid-to-apical anterior wall and apex, suggesting no viability in the LAD territory. (B) CMR images of a patient with occluded
proximal LAD with collaterals, 95% stenosis ostial LCX and occluded OM1, showing subendocardial scar from the basal to apical anterior wall, mid-
to-apical anteroseptal wall, and basal to mid-lateral wall involving < 50% myocardium, suggesting viability in the LAD and LCX territories. Given
these findings, the patient underwent coronary artery bypass graft. Reproduced from Erthal et al.,52 with permission from the International Journal of
Cardiovascular Sciences, used under CC BY 4.0.
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proximal left anterior descending (LAD) artery disease, as
these parameters are generally enough for clinicians to make
revascularization management decisions.22,29,34,67,68,72,82 On
the other hand, there is a growing number of patients with
diffuse epicardial CAD, microvascular disease, and/or sig-
nificant comorbidities such as advanced age or diabetes.
Based on post-hoc RCT data and observational data,
viability imaging may have value in patients with
IHF,3-5,16,18-20,28,53,56,57 butdas with any diagnostic
testdit should only be applied when it may have impacton management decisions. This may be the case in such
higher-risk cohorts, but further research is needed in these
populations to prove the potential benefit.
This field has evolved significantly over the past 20 years,
and future directions will explore personalized approaches to
revascularization in HF including the role of CTO/complex
anatomy, the method of revascularization, novel imaging
techniques, and serum biomarkers. The likelihood for
improvement in symptoms and prognosis is multifactorial. It
has been suggested recently that a comprehensive approach
that consideres clinical and imaging parametersdsometimes
Table 3. Findings on different imaging modalities for patients with





Reversible ischemia or > 20% of
the LV shown as viable
Single-photon emission computed
tomography
Reversible ischemia or a large
segment of viable myocardium
(> 30% of the LV)
Positron emission tomography Reversible ischemia or > 7% to
10% hibernating myocardium
(or  27% scar, assuming LV
dysfunction due to IHD)
CMR/LGE imaging Less than 50% wall-thickness
scarring shown by LGE in  4
dysfunctional segments
CMR, cardiac magnetic resonance; IHD, ischemic heart disease; LGE,
late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular
ejection fraction.
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Volume 35 2019using multiple imaging modalitiesdprovides complementary
information that might improve prediction.57
The ongoing Imaging Modalities to Assist With Guiding
and Evaluation of Patients With Heart Failure (IMAGE-HF)
trial, AIMI-HF is an RCT and registry of patients with IHF
that compares standard care, which includes SPECT imaging
to define ischemia or viability to advanced imaging modalities
using PET or CMR. This study may shed light on the impact
of advanced-viability imaging on clinical outcomes (composite
of cardiac death, arrest, infarction and cardiac hospitalization)
(http://clinicaltrials.gov NCT01288560).
Further, beyond revascularization decisions, assessment of
contractile reserve,83 defining regional scarring,84-86 and septal
glucose metabolism87 have shown potential in resynchroniz-
ing therapy (CRT) decision making. Likewise contractile
reserve, extent of scar, metabolism in the myocardiumd
including the papillary musclesdcould, in theory, play a role
in predicting response and aiding decision making for
expanding catheter-based valvular interventions (eg, mitral clip
procedures, although studies to date have not reported data on
viability imaging).54,55 Prospective studies are required to test
these hypotheses.Table 4. Parameters for consideration when deciding which patients
may benefit from viability assessment52,63-65
Viability testing is usually not
needed and unlikely to add useful
information
Viability testing may add useful
information
Younger patients Older patients
HFrEF with > class II angina HFrEF without angina
Proven moderate-to-severe ischemia
on other testing
No evidence of ischemia; moderate
to large persistent perfusion
defects suggesting scar (but may
be hibernating)
Higher LVEF (> 40 %) Lower LVEF (< 40 %)
Left main coronary artery disease Chronic total occlusion
No or limited comorbidities Severe/multiple comorbidities (renal
insufficiency, COPD, previous
CABG)
CAD, coronary artery disease; COPD, chronic obstructive pulmonary
disease; HFrEF, heart failure with reduced ejection fraction; LVEF, left
ventricular ejection fraction; LVESVI, left ventricular end-systolic index.Patients with CTO
Although numerous registry studies have shown that suc-
cessful revascularization of CTOs can be associated with
favourable outcomes including improvement in LV function
and mortality,88,89 more recent RCTs have been more
sobering.90-92 The use of viability or ischemia imaging in
CTO trials has been limited. The Randomized Multicentre
Trial to Evaluate the Utilization of Revascularization or
Optimal Medical Therapy for the Treatment of Chronic
Total Coronary Occlusion (EuroCTO) had a requirement of
a noninvasive imaging test to assess myocardial viability in the
territory of the CTO if there were myocardial dysfunction.90
Patients with angina or angina equivalent symptoms (n ¼
396) without acute coronary syndrome were randomized for
PCI þ OMT vs OMT. The study demonstrated an
improvement in symptoms and quality of life. In EXPLORE,
patients with ST-elevation myocardial infarction (STEMI)
and concurrent CTOs were randomized to percutaneous
coronary intervention (PCI) of the CTO lesion early after
primary PCI, or no PCI of the CTO lesion. PCI to the CTO
lesion did not result in higher LVEF. However, a subgroup
analysis showed that if the CTO lesion was in the LAD artery,
PCI to the CTO lesion was associated with significantly
higher LVEF after 4 months. Baseline CMR was performed in
49% of patients. In dysfunctional segments with transmural
extent of infarction < 50% in the CTO territory, the CTO
PCI resulted in significantly better recovery of wall thickening
compared with no PCI.91 However, the Recovery of Left
Ventricular Function After Stent Implantation in Chronic
Total Occlusion of Coronary Arteries (REVASC) showed that
PCI of CTO lesions did not improve either CMR-assessed
segmental or global LV function at 6 months, but there was
little room for improvement, as baseline LVEF was > 43%
and one third had no segmental wall-motion abnormalities.92
Although these trials used viability imaging as part of
enrollment criteria, none of the trials was performed specif-
ically in patients with significantly impaired LVEF with large
territories subtended by a CTO and proven viability, whereby
successful PCI may be expected to lead to a meaningful in-
crease in LVEF. Indeed, the mean LVEF in EXPLORE was
41% in the PCI arm before randomization, and that of
REVASC was > 55%.
One potential utility of viability testing in the presence of a
CTO is to enable appropriate clinical decisions on revasculari-
zation strategy for concurrent multivessel CAD. Collateral cir-
culation assessed by angiogram is not an effective way to assess
viability in CTOs,64,65,93 but viability imaging using thallium-
201 SPECT, FDG-PET, or CMR can predict functional
recovery accurately after revascularization.65,94,95 Prospective
studies underway will assess whether viability/ischemia testing
can detect which patients benefit from CTO PCI.96Serum Biomarkers
High-sensitivity troponins and N-terminal pro-type natri-
uretic peptide (NT-pro-BNP) have emerged as powerful
prognostic markers in heart failure,97 with elevated levels seen
in situations with myocardial supplyedemand mismatch,
increased myocyte turnover, myocardial apoptosis, wall stress,
and oxidative stress: processes similar to hibernation. In a pilot
study of 49 patients with IHF, LVEF  45%, the presence
Figure 4. Proposed algorithm for the integration of ischemia/viability testing in guiding revascularization decisions in ischemic cardiomyopathy.
*Including chronic total occlusions. ** > 50% Left main/proximal left anterior descending (LAD) coronary artery stenosis. ***Ischemia/viability
testing may be considered depending on patient, anatomy, targets, and revascularization risk. **** For eligible candidates. EF, ejection fraction;
CAD, coronary artery disease; (þ) presence of, () absence of. Modified from Wiefels et al.46 with permission form Springer Nature. Based on
Neumann et al.68 and the clinical evidence from observational data and guidelines discussed in this article.
Kandolin et al. 1025
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high-sensitivity troponin T (hsTnT) and NT-pro-BNP levels
independent of EF, age, and estimated glomerular filtration
rate (eGFR), as well as the presence of scar98 raising the
theoretical possibility to combine image-guided approach with
biomarker-guided approach to assist decision making.99 At
present, the evidence is limited.100,101 The ongoing Role of
Biomarkers in Alternative Imaging Modalities in Ischemic
Heart Failure (Bio-AIMI-HF) substudy of the IMAGE-HF
trial noted above will help to answer whether these and
other biomarkersdwith or without imagingdcan better
predict which patients will benefit from revascularization.Method of Revascularization
According to the current guidelines, CABG is recom-
mended as the first revascularization strategy in patients with“LVEF  35%, multivessel disease and acceptable surgical
risk.”68 However, CABG vs PCI randomized trials have
excluded patients with severe HF. The ongoing Study of
Efficacy and Safety of Percutaneous Coronary Intervention
to Improve Survival in Heart Failure (REVIVED-BCIS2)
will be the first randomized study on the impact of
revascularisation with PCI on the outcome of patients with
severe IHF and will also investigate viability specifically in
segments amenable to revascularization.102Novel Imaging Techniques
Novel hybrid/fusion imaging techniques; PET/CMR,
PET/CT, and stress-CMR will enable simultaneous assess-
ment of different aspects of viability: metabolism, perfusion,
and anatomy. Sympathetic denervation imaging might also
serve as a novel method of risk stratification and therapeutic
1026 Canadian Journal of Cardiology
Volume 35 2019target in patients with IHF, particularly around the prediction
of risk for sudden cardiac death.78Heart Team and Artificial Intelligence
Approaches for Complex Decisions
The importance of a heart team combining expertise of
HF, imaging, both surgical and interventional revasculariza-
tion, as well as anaesthesiologists and gerontologists, cannot be
overemphasized in making best decisions for these pa-
tients.67,103,104 Ottawa-5 exemplified how the combined role
of these experts with accessibility of technology could lead to
outcome benefit.28 In the future, machine learning/artificial
intelligence may increase the diagnostic performance of any
mode of (viability) imaging,105 which may be further inte-
grated for complex clinical decision making and a personalized
approach to revascularization.Conclusions
Definitive proof of whether viability imaging offers
outcome benefit in patients with HF has been elusive. It is
likely that, in the past, there was an over-reliance on viability
information that was not needed to guide decisions in many
patients. At present, decisions are made balancing patient-
related factors, risks of the intervention, anatomic data,
functional data, and patients’ perspectives. Viability imaging
should be limited to situations in which revascularization
decisions are most difficult. Physicians should consider
viability imaging when imaging findings will have impact on
decision making. The results from ongoing trials and future
evidence regarding the role in certain patient populations or
clinical scenariosdas well as the roles of biomarkers, neuro-
hormonal imaging, and artificial intelligencedwill provide
much-needed evidence to optimize revascularization decision
algorithms in this difficult patient population.Acknowledgements
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